Pacific Biosciences Of California (PACB) Total Debt (2010 - 2023)

Pacific Biosciences Of California's Total Debt history runs 13 years deep, the most recent figure standing at $500000.0 for Q4 2023.

• On a quarterly basis, Total Debt fell 99.71% year-over-year to $500000.0 in Q4 2023; TTM through Dec 2023 was $500000.0, a 99.71% decrease from a year earlier, with the FY2023 full-year figure at $500000.0, down 99.71% from the prior year.
• Total Debt eased to $500000.0 in Q4 2023 per PACB's latest filing, from $96.2 million in the prior quarter.
• Across five years, Total Debt topped out at $645.3 million in Q2 2023 and bottomed at $500000.0 in Q4 2023.
• The 4-year median for Total Debt is $96.2 million (2023), against an average of $160.1 million.
• Across the five-year window, Total Debt soared 4362.49% in 2022 and sank 99.71% in 2023, its largest moves.
• Year by year, Total Debt stood at $15.8 million in 2019, then plunged by 75.27% to $3.9 million in 2021, then surged by 4362.49% to $174.4 million in 2022, then sank by 99.71% to $500000.0 in 2023.
• Per Business Quant, the three latest PACB Total Debt figures stand at $500000.0 (Q4 2023), $96.2 million (Q3 2023), and $645.3 million (Q2 2023).